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Treatment of Chloroquine-Resistant Plasmodium vivax with Chloroquine and 
Primaquine or Halofantrine 
J. Kevin Baird, Hasan Basri, Budi Subianto, 
David J. Fryauff, Peter D. McElroy, Budhi Leksana, 
Thomas L. Richie, Sofyan Masbar, F. Stephen Wignall, 
and Stephen L. Hoffman 
US Naval Medical Research Unit 2, Jakarta, and Provincial Health 
Service, Jayapura, Irian Jaya, Indonesia; Naval Medical Research 
Institute, Bethesda, Maryland 
Optimal therapy for infection by chloroquine-resistant Plasmodium vivax has not been estab- 
lished. From 1992 to 1994 during three separate studies, 147 Javanese residents of Irian Jaya 
infected by P. vivax were treated with either chloroquine (25 mg of base/kg during 3 days or 10 
mg of base/kg in one dose) plus primaquine (10 mg/kg during 28 days or 2.5 mg/kg during 3 
days) (n = 78), chloroquine plus placebo (n = 50), or halofantrine (24 mg base/kg in 12 h; n = 19). 
There was no difference in tolerance to or side effects of any of the regimens. Within 14 days of 
starting therapy, therapeutic failure among these patients was 4407o for chloroquine, 50Zo for 
chloroquine plus primaquine (P < .001), and 0 for halofantrine (P < .001). After 28 days, thera- 
peutic failure was 7807o, 1507o, and 60Zo, respectively. Thus, chloroquine plus primaquine in combi- 
nation and halofantrine alone are effective therapies for chloroquine-resistant P. vivax. 
Resistance to chloroquine by Plasmodium vivax occurs in 
Southeast Asia and the southwest Pacific region [1,2]. The 
infection develops despite standard chloroquine prophy- 
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laxis, and parasitemia persists or recurs within 14 days after 
initiation of standard chloroquine therapy. Alternative drugs 
for chloroquine-resistant P. vivax have not been evaluated. 
Resistance to chloroquine by P. vivax in the absence of spe- 
cific therapies known to be effective threatens the health of 
the millions of people exposed to this infection. We investi- 
gated chloroquine plus primaquine in combination and 
halofantrine alone as therapies for chloroquine-resistant 
P. vivax. 
Materials and Methods 
Study sites and subjects. Between July 1992 and June 1994, 
studies were done at three villages in the Arso region of north- 
eastern Irian Jaya, Indonesia, where P. vivax is endemic [3]. The 
villages were 7- to 18-month-old settlements of people from 
Java and other islands. Subjects were ̂ 6 years old with asexual 
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parasitemias of P. vivax demonstrable by light microscopy (MO 
asexual parasites//uL of blood) of Giemsa-stained blood films 
read by experienced microscopists. A history of recent chloro- 
quine consumption did not disqualify subjects. All subjects were 
screened for glucose-6-phosphate dehydrogenase deficiency us- 
ing an NADPH spot test (Sigma, St. Louis). 
Studies I and II. Two studies of identical design were done 
at two villages in 1992 and 1993. Patients infected with P. vivax 
received standard chloroquine (25 mg/kg in three doses over 48 
h) and a placebo of primaquine (n = 27), standard chloroquine 
therapy plus 0.5 mg/kg primaquine base daily for 14 days fol- 
lowed by 0.5 mg/kg primaquine on alternate days for 13 days (a 
= 30), or 10 mg/kg chloroquine base in a single dose plus the 
regimen of primaquine above (n = 26). On day 0, all subjects 
began therapy with chloroquine (P.T. Bayer Indonesia, Jakarta; 
uncoated tablets, 150 mg of base). Receipt of daily primaquine 
(Sanofi-Winthrop, New York; sugar-coated tablets, 15 mg of 
base) or daily placebo (starch and amylose; Kimia Farma, Ban- 
dung, Indonesia) was randomized by blindly drawing a coded 
card. The code was unknown to subjects and to the research 
team. 
A blood film for parasitologic examination and a 100-;iL blot 
of blood on filter paper (no. 1; Whatman, Clifton, NJ) for assay 
of chloroquine were collected before administration of the first 
dose of chloroquine on day 0. A second IOO-/1L blot of capillary 
blood was collected on day 2, 4 h after administration of the last 
dose of chloroquine. Study subjects were examined on days 0, 1, 
2, 4, 7, 11, 14, 18, 21, 25, and 28 or at any time that they again 
exhibited symptoms of malaria. Symptomatic patients (chills, 
fever, or malaise) with detectable parasitemia were given qui- 
nine therapy after obtaining a 100-jliL blot of blood for measure- 
ment of blood chloroquine levels. 
Study III. Based on results of studies I and II, a third study 
was done in the Arso region in 1994. Patients with P. vivax 
parasitemia were randomized to receive either standard chloro- 
quine plus three doses of placebo during 48 h (n ̂  23), standard 
chloroquine plus three doses (two 1.0 mg/kg, one 0.5 mg/kg) of 
primaquine base at 24-h intervals (n = 22), or three doses of 
halofantrine (n = 19; SmithKline Beecham, UK; 500 mg of 
base, uncoated tablet) at 6-h intervals. Subjects were followed 
for 28 days and sampled as in studies I and II. 
Assay of chloroquine in blood. Collection and analysis of 
whole blood specimens for chloroquine and desethylchloro- 
quine was done as described [3] using high-performance liquid 
chromatography (Bio-Rad Laboratories, Richmond, CA). 
Analysis of therapeutic outcome. Persistence or recurrence of 
P. vivax parasitemia within 28 days after starting therapy was 
considered a therapeutic failure. The cumulative incidence of 
therapeutic failure within groups and the ratio of incidence den- 
sity (relative risk) among groups summarized outcomes. The 
significance of the relative risks and confidence intervals was 
obtained using Epistat 5.01b (CDC, Atlanta; WHO, Geneva). 
The significance of differences between means (geometric 
mean, log-transformed ata) was estimated by the two-tailed 
Student's t test. 
Subjects with intercurrent Plasmodium falciparum parasite- 
mia remained in the analysis of the cohort up to the point of 
quinine therapy. In these instances, the product of 0.5 (assumed 
midinterval withdrawal) and the number of withdrawals per 
week was subtracted from the denominator used to calculate the 
cumulative incidence. The 14- or 28-day cumulative incidence 
of therapeutic failure was calculated using standard life table 
calculations of weekly intervals [4]. 
Results 
Study subjects. Among chloroquine plus placebo, chloro- 
quine (25 mg/kg) plus primaquine, and chloroquine (10 mg/ 
kg) plus primaquine groups in studies I and II, subjects were 
predominantly male (23 vs. 7 female, 23 vs. 4, 25 vs. 1, 
respectively) and ranged in age from 6 to 51 years (means, 
24, 21, and 23, respectively; P = .222). Geometric mean 
parasite counts were 650, 1307, and 1618 trophozoites/ziL 
(P = .123), respectively. Eleven of the 83 subjects had mixed 
infections with P. falciparum and P. vivax at enrollment. Fig- 
ure 1A shows the mean levels of chloroquine in blood at 
enrollment and on day 2 among groups. 
Among chloroquine plus placebo, chloroquine (25 mg/ 
kg) plus primaquine (2.5 mg/kg), and halofantrine groups in 
study III, subjects were predominantly male (17 vs. 5 female, 
17 vs. 6, and 12 vs. 7, respectively) and ranged in age from 7 
to 54 years (means, 26, 27, and 27, respectively; P = .311). 
Geometric mean parasite counts were 608, 555, and 367 
trophozoites/juL (P = .1821), respectively. Five of the 64 
subjects had mixed infections with P. falciparum and P. vivax 
at enrollment. Figure 1B shows the mean levels of chloro- 
quine in blood at enrollment and on day 2 among groups. 
Posttherapeutic parasitemias. All subjects in studies I 
and II receiving chloroquine plus primaquine cleared para- 
sitemias within 5 days. Four patients receiving chloroquine 
plus placebo had asexual parasitemias that failed to clear by 
day 7. 
All patients in study III cleared asexual parasitemias by 
day 4, and none reappeared by day 7. The first recurrent 
parasitemias appeared on day 11 in 2 patients who received 
chloroquine plus placebo. 
Table 1 summarizes the cumulative incidence analysis of 
P. vivax therapeutic failure among subjects in the studies 14 
and 28 days after the start of therapy. The relative risk of 
therapeutic failure among subjects taking chloroquine plus 
placebo was 8-fold higher than that among patients given 
chloroquine plus primaquine at both day 14 and day 28. 
When the data from the studies were combined, the 14-day 
crude failure rate, which excludes withdrawals from the anal- 
ysis, was 44*30 among the 48 subjects given standard chloro- 
quine therapy, 57c among the 74 subjects given primaquine, 
and 0 among the 19 subjects given halofantrine. The 28-day 
crude failure rate was 78# among the 45 subjects given stan- 
dard chloroquine therapy, 157c among the 68 subjects given 
primaquine, and 67c among the 17 subjects given halofan- 
trine. 
Symptoms and signs after treatment. There was no indica- 
tion that any treatment regimen was associated with more 
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Day Post-Therapy Day Post-Therapy 
Figure 1. Measurements of chloroquine and desethylchloroquine among treatment groups in studies I and II (A) and III (B). Points at 
days 0 and 2 represent mean (?SD) chloroquine -I- desethylchloroquine level of groups (n = 17-22). All other points represent measure- 
ments of chloroquine 4- desethylchloroquine after onset of recurrent P. vivax parasitemia among individual subjects. CQ, chloroquine; PQ, 
primaquine; PL, placebo; HF, halofantrine. Numbers in parentheses refer to total doses (mg/kg). 
side effects than any other regimen. Malaise, fever, chills, or 
headache persisted through the 48 h after starting therapy 
among 20% (6/30), 23% (6/26), and 22% (6/27) of subjects 
receiving chloroquine plus placebo, chloroquine (25 mg/kg) 
plus primaquine, and chloroquine (10 mg/kg) plus prima- 
quine in studies I and II. There were also no differences in 
Table 1. Treatment of chloroquine-resistant P. vivax with chloroquine, chloroquine plus primaquine, or halofantrine. 
14 days 28 days 
No. with No. with 
Study, treatment No. treatment CIF No. treatment CIF 
regimen (n) withdrawing failure (%) RR(95%CI) P* withdrawing failure (%) RR(95%CI) P* 
Studies I and II 
CQ25 + PL(27) 2 14 53 4 20 80 
CQ25 + PQ.o (30) 2 2 7 8.38(1.7-27.0) .021 4 4 15 7.69(4.5-14.0) <.001 
CQ.o + PQ10 (26) 1 2 8 7.63(0.7-18.0) .004 3 3 13 8.33(4.5-17.0) <.001 
Study III 
CQ25 + PL(23) 0 7 31 1 15 69 
CQ25 + PQ2.5 (22) 1 0 7 >7.0? .015 3 3 16 5.00(2.9-9.0) <.001 
HF(19) 0 0 8 >7.0? .036 2 1 6 12.5(5.3-33.0) <.001 
NOTE. CQ, chloroquine; PL, placebo; PQ, primaquine; HF, halofantrine; subscript numbers refer to total dose (mg/kg). Withdrawals were due to 
intercurrent parasitemia by Plasmodium falciparum; treatment failure, persistent or recurrent parasitemia by P. vivax. CIF, 14- or 28-day cumulative incidence 
of therapeutic failure. RR, risk of parasitemia in placebo group relative to PQ or HF groups (CI, confidence interval). * Calculated by two-tailed Fisher's exact test. 
CQ+DCQ 
(ng/ml 
blood) 
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relief of symptoms among the groups in study III (data not 
shown). Incidence density analysis revealed no differences 
among treatment regimens for overall symptoms during the 
remainder of the 28-day test (P = .298). 
Chloroquine and desethylchloroquine blood levels. Figure 
1 illustrates the sum of chloroquine and desethylchloroquine 
levels in whole blood before chloroquine therapy (day 0), 4 h 
after the last dose of supervised chloroquine therapy (day 2), 
and after the onset of recurrent parasitemia (days 7-28). At 
the time of enrollment, many subjects with P. vivax parasite- 
mia had levels of chloroquine in their blood considered 
therapeutic (53% had MOO ng/mL chloroquine plus 
desethylchloroquine). Subjects had normal absorption of 
chloroquine (456-6257 ng/mL chloroquine plus deseth- 
ylchloroquine at day 2; mean, 1932). Chloroquine levels be- 
fore and after therapy were similar in the chloroquine plus 
primaquine and chloroquine plus placebo groups (P = .578). 
The day 2 mean level of chloroquine plus desethylchloro- 
quine among subjects who received only 10 mg/kg chloro- 
quine was indistinguishable from that among patients who 
received 25 mg/kg chloroquine plus primaquine or placebo 
(P = .3422). Most therapeutic failures occurred with MOO 
ng/mL chloroquine plus desethylchloroquine in whole 
blood. Ratios of chloroquine to desethylchloroquine (mean, 
3.1) did not differ between primaquine and placebo on day 2 
in studies I and II (P = .450) or III (P = .558). 
Discussion 
These studies demonstrate that the combination of 25 mg/ 
kg chloroquine base and 2.5 mg/kg primaquine base admin- 
istered in three divided doses during 48 h or 24 mg/kg halo- 
fantrine base administered in three divided doses during 12 h 
is effective treatment for chloroquine-resistant P. vivax ma- 
laria in Irian Jaya, Indonesia. The data also show that the 
chloroquine plus primaquine combination is as well-toler- 
ated as chloroquine alone. The rate of therapeutic failure 
after treatment with a single dose of 10 mg/kg chloroquine 
base plus primaquine was similar to the resistance to 25 mg/ 
kg chloroquine plus primaquine therapy. However, the lev- 
els of chloroquine on day 2 were similar between these 
groups, presumably because of the relatively high levels of 
chloroquine in the blood of most volunteers on day 0 due to 
self-medication. Therefore, we cannot conclude that a single 
dose of 10 mg/kg chloroquine in combination with prima- 
quine would be adequate in persons with no chloroquine in 
their blood before therapy. 
Primaquine at therapeutic doses has long been considered 
an exclusively tissue-schizonticidal drug, that is, eliminating 
infected hepatocytes without killing blood-stage asexual para- 
sites [5]. After studies I and II, we considered the possibility 
that primaquine worked by preventing early relapse or rein- 
fection but not by attacking infected erythrocytes. However, 
we believe that when primaquine is used with chloroquine 
against resistant P. vivax, the efficacy of this combination is 
due to activity directed against infected erythrocytes rather 
than infected hepatocytes. If the high therapeutic failure rate 
in the chloroquine plus placebo groups is linked to resistance 
to chloroquine by asexual blood forms of P. vivax, then supe- 
rior efficacy of chloroquine plus primaquine against resistant 
blood-stage parasites would explain the low rate of therapeu- 
tic failure. 
Several observations show that blood-stage resistance to 
chloroquine by P. vivax predominated among the patients in 
Irian Jaya. First, among 312 patients infected by P. vivax 
(most acquired naturally in tropical Asia and the South Paci- 
fic), none had a recurrent parasitemia before day 17 after 
initiating demonstrably effective quinine therapy [6-12]. 
Therefore, recurrent parasitemias within 14 days of starting 
chloroquine therapy, as among 44% of patients given chloro- 
quine plus placebo, almost certainly represent recrudescence 
by P. vivax. Second, among 245 patients infected by P. vivax 
from the southwest Pacific during World War II and treated 
with chloroquine, none had recurrent parasitemia before day 
30 after the start of therapy [6-12]. Therefore, recurrences 
within 30 days of starting chloroquine therapy constitute di- 
rect evidence of resistance; the 28-day cumulative incidence 
of recurrent parasitemia among the patients in Irian Jaya was 
70% (crude failure rate of 78%, i.e., 35 failures among 45 
complete tests). All except 3 recurrences of parasitemia in 
our studies occurred in the face of ordinarily suppressive lev- 
els of chloroquine in blood (figure 1). 
Third, exposure of the study subjects to reinfection during 
our studies was much too low to account for the differences 
between the primaquine and placebo groups. In two studies, 
the incidence of P. vivax in the Arso region ranged from 0.6 
to 1.25 infections/person-year [13]. Thus, among the 50 sub- 
jects in the chloroquine plus placebo groups (3.8 person- 
years of follow-up), 4 reinfections would be expected, 
whereas 35 recurrences appeared. In summary, relapse or 
reinfection could not account for the very large difference in 
therapeutic failure rates between the chloroquine plus pla- 
cebo and chloroquine plus primaquine groups, both contain- 
ing subjects infected with ~70% chloroquine-resistant P. vi- 
vax. The basis of that difference appears to be superior blood 
schizonticidal activity by chloroquine plus primaquine ver- 
sus chloroquine plus placebo. 
Combined chloroquine and primaquine therapy act addi- 
tively or synergistically against chloroquine-resistant P. vivax 
infections. Studies of chloroquine and primaquine treatment 
of the chloroquine-resistant NS strain of Plasmodium yoelii 
in mice support the interpretation of synergy [14]. A clinical 
study of P. vivax in Thailand showed surprising blood schi- 
zonticidal activity of primaquine alone [ 15], but those pa- 
tients could have had low levels of self-administered chloro- 
quine in their blood. Determination of whether chloroquine 
and primaquine function additively or synergistically against 
chloroquine-resistant P. vivax and of how much activity pri- 
1682 Concise Communications JID 1995;171 (June) 
maquine actually has on its own against chloroquine-resis- 
tant P. vivax must await further investigation. 
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